单克隆抗体
癌症研究
抗体
单克隆
肺
免疫疗法
抗原
作者
Yunes Panahi,Amir Hossein Mohammadzadeh,Behzad Behnam,Hossein M. Orafai,Tannaz Jamialahmadi,Amirhossein Sahebkar
标识
DOI:10.1007/978-3-030-55035-6_3
摘要
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects, using targeted treatments alongside chemoradiation has shown a better outcome in terms of progression and quality of life for patients. These targeted treatments include small biological inhibiting molecules and monoclonal antibodies. In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI